Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections

Heart

Volumn 76, Issue 5, 1996, Pages 418-421

  Günal, A Ihsan ^a   Içik, Ahmet ^a   Çeliker, Hüseyin ^a   Eren, Orhan ^a   Çelebi, Harika ^a   Günal, Servin Y ^a   Lüleci, Cemal ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Hypertrophic cardiomyopathy; Octreotide

Indexed keywords

OCTREOTIDE; PROPRANOLOL; SOMATOSTATIN DERIVATIVE; VERAPAMIL;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE MASS; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL;

EID: 0029801055     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.5.418     Document Type: Article

References (26)

1. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43: 42-1244.
2. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.
3. Yoshiriori K, Morio I, Hironori T. Increased cardiovascular response to epinephrine in hypertrophic cardiomyopathy. Jpn Heart J 1985;26:727-40.
4. Brush JE, Eisenhofer G, Garty M, Stull R, Maron BJ, Canon RO, et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 1987;79:836-44.
5. Pearce PC, Hawkey C, Symons C, Olsen EGJ. Role of calcium in the induction of cardiac hypertrophy and myofibrillar disarray. Br Heart J 1985;54:420-7.
6. Witzke AH, Kaye MP. Myocardial ultrastructural changes induces by administration of nerve growth factor. Surg Forum 1976;27:295.
7. Toyozaki T, Hiroe M, Hasumi M, Horie T, Husoda S, Tsushima T, at al. Insulin-like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993;57:1120-7.
8. Sakata Y. Tissue factor contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO 14-6): involvement of transforming growth factor-beta I and tissue reninangiotensin system in the progression of cardiac hypertrophy. Hokkaido Igaku Zasshi 1993;68:18-28.
9. Grant MB, Wargovich TJ, Ellis EA, Caballero BS, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. Circulation 1994;89: 1511-7.
10. Zink A, Rause F. Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6-23 cells: possible involvement of a pertussis toxin-sensitive G-protein. Acta Endocrinologia 1992;127:378-84.
11. Tokgözog̃lu SL, Erbas T, Aytemir K, Akalýn S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994;74:1072-4.
12. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;77:790-3.
13. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117:719-26.
14. Opie LH. Angiotensin converting enzyme inhibitors. New York: Authors' Publishing House. 1992;21-153.
15. McAreavey D, Robertson JS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990;40:326-45.
16. Sahn DJ, DeMaria A, Kisslo J. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
17. Devereux RB, Alonso DR, Lutas EM, Goltlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
18. Wynne S, Braunwald E. Hypertrophic cardiomyopathy. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders, 1992;1412-3.
19. Maron BJ, Bonow CO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology and therapy. N Engl J Med 1987;316:780-9; 844-52.
20. McIntosh CL, Moron BJ. Current operative treatment of hypertrophic obstructive cardiomyopathy. Circulation 1988;78:487.
21. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988;9:417-36.
22. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989;16:95-115.
23. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.
24. Cool DE, Andreassen PR, Tonks NK, Krebs EG, Fischer EH, Morgolis RL. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosine-phosphates. Proc Natl Acad Sci USA. 1992;89:5422-6.
25. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-I: a potential pituitary-independent mechanism for drug action. J Clinical Endocr Metab 1992;75:1459-63.
26. Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow CO, Watson RM. Myocardial ischemia in hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.